Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Triple meeting 2025 – Halda’s proximity play in prostate
Early data with the RIPTAC HLD-0915 look competitive.
Blenrep against the odds
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
Tango waltzes towards phase 3
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
A cautionary tale for clinical trial collaborators
AstraZeneca ended a tie-up with Asher, and then set off on its own.
GSK prepares its kit in GIST
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
Triple meeting 2025 – Revolution hints at post-KRAS promise
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
ESMO 2025 – Sanofi takes aim at Lutathera
But Perspective sinks again.
Bispecific cytokine delivers for Innovent at last
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
